Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 795 participants.

Also called NCT01174693

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 795 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01174693
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01174693. Randomized; no masking; primary purpose treatment. Start 2010-03 (registry gives no type); primary completion 2014-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Triflusal and Clopidogrel in Secondary Prevention of Stroke Based on the Genotyping
Acronym
MAESTRO
Condition
Cerebral Infarction
Intervention (Drug)
Triflusal
Intervention (Drug)
Clopidogrel
Lead sponsor
Gangnam Severance Hospital (class: other)
Collaborator
Myung In Pharmaceutical Company (class: not stated)
Collaborator
Yonsei University (class: other)

Record details

Record id
cardio:ct-nct01174693
Content hash
dbdbe190069cdcb20ca037498b3b61e220b5ed1af1286914f4691287244efdf8